LEXXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Lexaria Bioscience Corp. hold a median 12-month price target of $52 — +381.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lexaria Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LEXX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +381.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $1.50 |
| 29 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 July 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Mar 2024 | Maxim Group | Maintains | Buy | — |
| 21 July 2023 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LEXX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 4% of US stocks
Cheaper than 28% of US stocks
Cheaper than 71% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 99% of US stocks
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexaria Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares rallied Thursday after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd.
Why it matters — The agreement with PegBio could signal a new strategic partnership or development milestone for Lexaria.
Lexaria Bioscience has entered a Material Transfer Agreement with PegBio to evaluate its DehydraTECH drug delivery platform using a PegBio molecule being developed for the GLP-1 space. This agreement is separate from and unrelated to Lexaria's existing MTA with another pharmaceutical company.
Why it matters — This expands Lexaria's partnership pipeline within the high-demand GLP-1 drug sector without disrupting its existing agreements.
Lexaria Bioscience Corp. announced a reverse stock split of its common stock, effective 12:01 am EST on August 3, 2026, aimed at boosting the per-share market price to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
Why it matters — A reverse stock split directly affects Lexaria's Nasdaq listing status and share price, making it a critical corporate action for current shareholders.
The 1 Wall Street analysts covering Lexaria Bioscience Corp. have a median 12-month price target of $52, with estimates ranging from $22 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Lexaria Bioscience Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexaria Bioscience Corp. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Lexaria Bioscience Corp. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +381.0% from the last close, and Ticker Nerd's factor model ranks Lexaria Bioscience Corp. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lexaria Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LEXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $82 over the next 12 months.
Lexaria Bioscience Corp. returned -7.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH.
The most recent item we track (Benzinga, 13 Aug 2026): "Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know". Lexaria Bioscience Corp. (NASDAQ:LEXX) shares rallied Thursday after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd.
Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.
CEO Mr. Richard C. Christopher · 7 employees · Canada · https://lexariabioscience.com